Betulinaldehyde Ameliorates Aβ-Induced Neurotoxicity and Cognitive Deficits by Modulating the eEF2K/eEF2 Pathway

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) lacks effective treatments, with the eEF2K/eEF2 pathway implicated in neuronal dysfunction.
• Limited pharmacological options exist to target the eEF2K/eEF2 pathway in AD.
• Betulinaldehyde (Betu), a compound from traditional Chinese medicine, requires evaluation for neuroprotective potential.

Purpose of the Study:

• To investigate the therapeutic effects of Betu on AD.
• To determine if Betu's effects are mediated via the eEF2K/eEF2 pathway.

Main Methods:

• Utilized neuronal cell models to assess Betu's impact on Aβ42-induced neurotoxicity, dendritic spine damage, and protein synthesis.
• Employed eEF2K agonists and protein synthesis inhibitors to probe pathway involvement.
• Conducted cellular thermal shift assay (CETSA) to detect Betu-eEF2K interactions.
• Evaluated Betu's effects on reactive oxygen species (ROS) and downstream signaling.
• Assessed Betu's efficacy in an Aβ42-induced AD mouse model for cognitive and neuropathological improvements.

Main Results:

• Betu significantly protected against Aβ42-induced neuronal death and dendritic spine damage.
• Betu restored protein synthesis and reversed eEF2 hyperphosphorylation, effects dependent on the eEF2K/eEF2 pathway.
• CETSA indicated a potential interaction between Betu and eEF2K.
• Betu reduced Aβ42-induced ROS accumulation and modulated related signaling pathways.
• In vivo, Betu ameliorated cognitive decline and hippocampal damage in an AD mouse model.

Conclusions:

• Betu demonstrates significant neuroprotective effects against Aβ42-induced toxicity.
• The findings confirm Betu's mechanism involves modulating the eEF2K/eEF2 pathway.
• Betu shows promise as a lead compound for developing novel Alzheimer's disease therapies.